Wordt geladen...
Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both
The English High Court recently dismissed the Bayer pharmaceutical company’s challenge against a regional clinical commissioning group’s policy allowing NHS Trusts to use a cheaper, but unlicensed, alternative to a sight preserving eye treatment. This makes sober reading for companies marketing “on-...
Bewaard in:
| Gepubliceerd in: | Eye (Lond) |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group UK
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6461787/ https://ncbi.nlm.nih.gov/pubmed/30498264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41433-018-0280-3 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|